Skip to main content
Top
Published in: Virology Journal 1/2017

Open Access 01-12-2017 | Research

Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain

Authors: S. Perez, A. Iñarrea, R. Pérez-Tanoira, M. Gil, E. López-Díez, O. Valenzuela, M. Porto, L. Alberte-Lista, M. A. Peteiro-Cancelo, A. Treinta, R. Carballo, M. C. Reboredo, M. E. Alvarez-Argüelles, M. J. Purriños

Published in: Virology Journal | Issue 1/2017

Login to get access

Abstract

Background

Human papillomavirus (HPV) bivalent and quadrivalent vaccines have been widely implemented in worldwide organized immunization programs. A nonavalent HPV vaccine is now available in several countries. The objective was to describe the fraction of squamous non-invasive high-grade cervical intraepithelial lesions attributable to genotypes targeted by bi-quadrivalent vaccines and by nonavalent vaccine according to age and diagnosis in women living in the city of Vigo (Galicia, Spain).

Methods

Cervical scrapings (2009–2014) of women with histological diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2, n = 145) and grade 3-carcinoma in situ (CIN3-CIS, n = 244) were tested with Linear Array HPV Genotyping test (Roche diagnostics, Mannheim, Germany). Hierarchical estimation of the fraction attributable to HPV 16/18 or HPV 31/33/45/52/58 detected alone or in combination was calculated. Absolute additional fraction attributable to genotypes targeted by nonavalent vaccine compared to genotypes targeted by bi-quadrivalent vaccines was calculated as the increment of attributable cases with respect to all studied cases. Age group 1, 2 and 3 included women 18 to 34, 35–44 and ≥45 years old, respectively. EPIDAT 3.1 was used.

Results

Fraction attributable to genotypes targeted by bi-quadrivalent vaccines was 59% CIN2 vs. 69% CIN3-CIS (p < 0.001). It was 63/51/50% of CIN2 and 78/66/45% of CIN3-CIS in age group 1, 2, 3, respectively. Fraction attributable to genotypes targeted by nonavalent vaccine was 86% CIN2 and 86% CIN3-CIS. It was 87/91/75% of CIN2 and 90/86/76% of CIN3-CIS in age group 1, 2, 3, respectively. Fraction attributable to genotypes targeted by these vaccines tended to decrease as age increased (p-trend <0.05). Globally, absolute additional attributable fraction was 16%, 26% and 29% in age group 1, 2 and 3, respectively (p < 0.005).

Conclusions

Absolute additional fraction of CIN2 and CIN3-CIS attributable to genotypes targeted by nonavalent vaccine was observed in women of any age, especially in those over 35 years old.
Literature
1.
go back to reference Van de Velde N, Boily M-C, Drolet M, Franco EL, Mayrand M-H, Kliewer EV, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012;104:1712–1723. Van de Velde N, Boily M-C, Drolet M, Franco EL, Mayrand M-H, Kliewer EV, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012;104:1712–1723.
2.
go back to reference Hartwig S, St Guily JL, Dominiak-Felden G, Alemany L, de Sanjosé S. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agents Cancer. 2017;12:19.CrossRefPubMedPubMedCentral Hartwig S, St Guily JL, Dominiak-Felden G, Alemany L, de Sanjosé S. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agents Cancer. 2017;12:19.CrossRefPubMedPubMedCentral
3.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. http://globocan.iarc.fr. Accessed 21 Jul 2014. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. http://​globocan.​iarc.​fr. Accessed 21 Jul 2014.
4.
go back to reference Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4:e453–63.CrossRefPubMed Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4:e453–63.CrossRefPubMed
7.
go back to reference Isidean SD, Tota JE, Gagnon JA, Franco EL. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Rev Vaccines. 2015;14:119–33.CrossRefPubMed Isidean SD, Tota JE, Gagnon JA, Franco EL. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Rev Vaccines. 2015;14:119–33.CrossRefPubMed
8.
go back to reference de Sanjose S, Wheeler CM, Quint WGV, Hunt WC, Joste NE, Alemany L, et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomark Prev 2013;22:1313–1318. de Sanjose S, Wheeler CM, Quint WGV, Hunt WC, Joste NE, Alemany L, et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomark Prev 2013;22:1313–1318.
9.
go back to reference Joste NE, Ronnett BM, Hunt WC, Pearse A, Langsfeld E, Leete T, et al. Human Papillomavirus Genotype-Specific Prevalence Across the Continuum of Cervical Neoplasia and Cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):230-40. Joste NE, Ronnett BM, Hunt WC, Pearse A, Langsfeld E, Leete T, et al. Human Papillomavirus Genotype-Specific Prevalence Across the Continuum of Cervical Neoplasia and Cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):230-40.
10.
go back to reference Veldhuijzen NJ, Berkhof J, Gillio-Tos A, Marco LD, Carozzi F, Mistro AD, et al. The age distribution of type-specific high-risk human Papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomark Prev. 2015;24:111–8.CrossRef Veldhuijzen NJ, Berkhof J, Gillio-Tos A, Marco LD, Carozzi F, Mistro AD, et al. The age distribution of type-specific high-risk human Papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomark Prev. 2015;24:111–8.CrossRef
11.
go back to reference Pérez-Castro S, Lorenzo-Mahía Y, Iñarrea Fernández A, Lamas-González MJ, Sarán-Díez MT, Rubio-Alarcón J, et al. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact. Enferm Infecc Microbiol Clin. 2014;32:479–85.CrossRefPubMed Pérez-Castro S, Lorenzo-Mahía Y, Iñarrea Fernández A, Lamas-González MJ, Sarán-Díez MT, Rubio-Alarcón J, et al. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact. Enferm Infecc Microbiol Clin. 2014;32:479–85.CrossRefPubMed
12.
go back to reference Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, et al. Detection and typing of human Papillomavirus by E6 nested multiplex PCR. J Clin Microbiol. 2004;42:3176–84.CrossRefPubMedPubMedCentral Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, et al. Detection and typing of human Papillomavirus by E6 nested multiplex PCR. J Clin Microbiol. 2004;42:3176–84.CrossRefPubMedPubMedCentral
13.
go back to reference IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.
14.
go back to reference Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, et al. Attribution of 12 high-risk human Papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomark Prev. 2014;23:1997–2008.CrossRef Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, et al. Attribution of 12 high-risk human Papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomark Prev. 2014;23:1997–2008.CrossRef
15.
go back to reference Santiago Pérez MI, Hervada Vidal X, Naveira Barbeito G, Silva LC, Fariñas H, Vázquez E, et al. The Epidat program. Rev Panam Salud Publica. 2010;27:80–2.CrossRefPubMed Santiago Pérez MI, Hervada Vidal X, Naveira Barbeito G, Silva LC, Fariñas H, Vázquez E, et al. The Epidat program. Rev Panam Salud Publica. 2010;27:80–2.CrossRefPubMed
16.
go back to reference Riethmuller D, Jacquard A-C, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, et al. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health. 2015;15:453.CrossRefPubMedPubMedCentral Riethmuller D, Jacquard A-C, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, et al. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health. 2015;15:453.CrossRefPubMedPubMedCentral
17.
go back to reference Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human Papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerging Infect Dis. 2016;22:56–64.CrossRefPubMedPubMedCentral Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human Papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerging Infect Dis. 2016;22:56–64.CrossRefPubMedPubMedCentral
18.
go back to reference Osborne SL, Tabrizi SN, Brotherton JML, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33:201–8.CrossRefPubMed Osborne SL, Tabrizi SN, Brotherton JML, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33:201–8.CrossRefPubMed
19.
go back to reference Pollock KGJ, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111:1824–30.CrossRefPubMedPubMedCentral Pollock KGJ, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111:1824–30.CrossRefPubMedPubMedCentral
20.
go back to reference Ali H, McManus H, O’Connor CC, Callander D, Kong M, Graham S, et al. Human papillomavirus vaccination and genital warts in young indigenous Australians: national sentinel surveillance data. Med J Aust. 2017;206:204–9.CrossRefPubMed Ali H, McManus H, O’Connor CC, Callander D, Kong M, Graham S, et al. Human papillomavirus vaccination and genital warts in young indigenous Australians: national sentinel surveillance data. Med J Aust. 2017;206:204–9.CrossRefPubMed
22.
go back to reference Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157–67.CrossRefPubMedPubMedCentral Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157–67.CrossRefPubMedPubMedCentral
Metadata
Title
Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
Authors
S. Perez
A. Iñarrea
R. Pérez-Tanoira
M. Gil
E. López-Díez
O. Valenzuela
M. Porto
L. Alberte-Lista
M. A. Peteiro-Cancelo
A. Treinta
R. Carballo
M. C. Reboredo
M. E. Alvarez-Argüelles
M. J. Purriños
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2017
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-017-0879-1

Other articles of this Issue 1/2017

Virology Journal 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.